Barclays analyst Saket Kalia raised the firm’s price target on Omada Health (OMDA) to $29 from $28 and keeps an Overweight rating on the shares. The company reported “another beat and raise” quarter, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA: